Loading…
XORTX Therapeutics Inc. is projected to rise to $2.84 by 2027, a +30% move from its current price of $2.18. XRTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.11 | $2.17 | $2.24 | -0.05% |
| Jul 14 | $2.08 | $2.17 | $2.27 | -0.11% |
| Jul 15 | $2.05 | $2.17 | $2.30 | -0.16% |
| Jul 16 | $2.04 | $2.17 | $2.31 | -0.21% |
| Jul 17 | $2.02 | $2.17 | $2.33 | -0.26% |
| Jul 18 | $2.00 | $2.17 | $2.35 | -0.32% |
| Jul 19 | $1.99 | $2.17 | $2.36 | -0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.99 | $2.17 | $2.36 | -0.37% |
| Week 2 | $1.91 | $2.16 | $2.43 | -0.74% |
| Week 3 | $1.86 | $2.15 | $2.49 | -1.10% |
| Week 4 | $1.81 | $2.14 | $2.54 | -1.47% |
| Week 5 | $1.77 | $2.14 | $2.58 | -1.83% |
| Week 6 | $1.73 | $2.13 | $2.62 | -2.20% |
| Week 7 | $1.69 | $2.12 | $2.65 | -2.56% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
XORTX Therapeutics Inc. is a healthcare company focused on the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. The company’s portfolio includes XRx-026, which is in Phase III for the treatment of gout; XRx-008, in Phase II for autosomal dominant polycystic kidney disease; XRx-101, in Phase II for acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; XRX-225, in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
The company is based in Calgary, Canada.
The description highlights a late-stage clinical pharmaceutical focus and a diversified pipeline targeting kidney and metabolic disorders. The company operates within the Healthcare category and trades under the symbol XRTX.
XORTX Therapeutics Inc. (XRTX) is a healthcare company with a current price of $2.04, a market capitalization of $3.53M, and a rank of 5408. The stock’s current price and market presence are noted alongside a diversified late-stage and preclinical development portfolio.
Forecasts present a nuanced price outlook. The 2026 average price is $2.04 with a 0% ROI and NEUTRAL sentiment, indicating the starting point of the forecast horizon. From 2027 onward, the model projects bullish momentum, with rising average prices and positive ROIs through 2050.
The long-range path shows the average price advancing to $3.03 by 2030 and continuing higher to $8.03 by 2050, with a max forecast of $16.13 in 2050 and an overall bullish sentiment across most years. These figures imply meaningful upside potential but remain subject to the usual investment uncertainties.
A major floor 20.7% below — a decisive break under it would weaken the trend.
The nearest floor, 6.2% below — buyers have tended to step in here.
The nearest ceiling, 5.7% above — a clean break opens room to run.
A major ceiling 39.3% above — clearing it would confirm fresh momentum.
Key XRTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XRTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.09 | Buy | $2.11 | Buy |
| MA 10 | $2.12 | Buy | $2.11 | Buy |
| MA 20 | $2.13 | Buy | $2.15 | Buy |
| MA 50 | $2.31 | Sell | $2.24 | Sell |
| MA 100 | $2.26 | Sell | $2.37 | Sell |
| MA 200 | $2.71 | Sell | $3.17 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.28 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 64.05 | Neutral |
| Williams %R (14) | -15.63 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 4.57 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 84.37 | Sell |
| TRIX (15) | -0.40 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 52.29 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 2.09 | Buy |
| ADX (14) | 11.87 | Neutral |
| ATR (14) | 0.05 | Info |
Near-term, the technical picture is NEUTRAL. The RSI14 sits at 40, indicating neither overbought nor oversold conditions.
The stock trades around key moving averages, with the SMA50 at $2.36 and the SMA200 at $2.74. The identified near-term support is $2.04 and resistance at $2.40, framing a modest trading band in the coming weeks.
In the last 30 days, the price range extended from a low of $1.63 to a high of $2.55, highlighting a broad but contained volatility environment over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.73 | $2.18 | $2.73 | 0% | Neutral | |
| $2.22 | $2.84 | $3.86 | +30% | Bullish | |
| $2.23 | $2.95 | $4.18 | +36% | Bullish | |
| $2.13 | $2.90 | $4.24 | +33% | Bullish | |
| $2.31 | $3.22 | $4.85 | +48% | Bullish | |
| $2.06 | $2.93 | $4.52 | +35% | Bullish | |
| $2.02 | $2.94 | $4.64 | +35% | Bullish | |
| $2.51 | $3.73 | $6.00 | +72% | Bullish | |
| $2.76 | $4.18 | $6.84 | +92% | Bullish | |
| $2.88 | $4.44 | $7.39 | +104% | Bullish | |
| $3.44 | $5.76 | $10.27 | +165% | Bullish | |
| $4.48 | $8.70 | $17.14 | +300% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.73 | $2.18 | $2.55 | +0.00% |
| August 2026 | $1.71 | $2.03 | $2.47 | -6.88% |
| September 2026 | $1.73 | $2.07 | $2.56 | +2.33% |
| October 2026 | $1.80 | $2.17 | $2.71 | +4.56% |
| November 2026 | $1.77 | $2.14 | $2.71 | -1.11% |
| December 2026 | $1.76 | $2.15 | $2.73 | +0.12% |
Click any year to see its month-by-month XRTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The XRTX price prediction for 2026 points to an average of $2.18 (low $1.73, high $2.73) — a potential gain of 0% on today's $2.18. A consolidation phase looks the most probable path here.
In 2027, XRTX is projected to trade between $2.22 and $3.86, averaging $2.84 — a potential gain of +30% from today's $2.18. That is up +30% on the projected 2026 average. Momentum favours further upside here.
XORTX Therapeutics Inc.'s 2028 outlook centres on $2.95, within a $2.23 to $4.18 range. That is up +4% on the projected 2027 average. That marks a +36% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, XRTX could reach as high as $4.24, with a base case around $2.90 and support toward $2.13 — roughly +33% from $2.18. Momentum favours further upside here.
Expect XRTX to range from $2.31 to $4.85 through 2030. The $3.22 average target implies a +48% move from current prices. That is up +11% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The XRTX price prediction for 2031 points to an average of $2.93 (low $2.06, high $4.52) — a potential gain of +35% on today's $2.18. Momentum favours further upside here.
In 2032, XRTX is projected to trade between $2.02 and $4.64, averaging $2.94 — a potential gain of +35% from today's $2.18. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
XORTX Therapeutics Inc.'s 2033 outlook centres on $3.73, within a $2.51 to $6.00 range. That is up +27% on the projected 2032 average. That marks a +72% change versus current levels. Momentum favours further upside here.
By 2034, XRTX could reach as high as $6.84, with a base case around $4.18 and support toward $2.76 — roughly +92% from $2.18. Buyers look set to stay in control over this stretch.
Expect XRTX to range from $2.88 to $7.39 through 2035. The $4.44 average target implies a +104% move from current prices. That is up +6% on the projected 2034 average. Momentum favours further upside here.
The XRTX price prediction for 2040 points to an average of $5.76 (low $3.44, high $10.27) — a potential gain of +165% on today's $2.18. Buyers look set to stay in control over this stretch.
In 2050, XRTX is projected to trade between $4.48 and $17.14, averaging $8.70 — a potential gain of +300% from today's $2.18. That is up +51% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in XRTX today (≈ 459.770115 XRTX) could be worth
$3,999.1
+$2,999.1 (+300%) by 2050 · US Dollar
Based on the average projected XRTX price of $8.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XRTXwould be worth at today's price.
$1,000 invested in XRTX on Jul 10, 2025 (≈ 229.885063 XRTX) would be worth
$500
-$500 (-50.0%) today · 0.50× · US Dollar
Based on a XRTX entry price of $4.35 vs. today's $2.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.07 | $1,050.72 | +5.1% |
| 1 month ago | $2.28 | $953.95 | -4.6% |
| 3 months ago | $2.49 | $873.49 | -12.7% |
| 6 months ago | $2.9 | $748.71 | -25.1% |
| 1 year ago | $4.35 | $500 | -50.0% |
| All time (4.8y) ago | $2,030.27 | $1.07 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XRTX forecast.
Our base-case forecast reaches $4.30 around 2035.
Implied market cap at $4.30: $7.44M
The multi-year forecast paints a bullish trajectory across the horizon. In 2026 the average price is $2.04 with a 0% ROI and NEUTRAL sentiment, followed by a path of gains through the late 2020s and early 2030s.
By 2027 the average is projected at $2.67 with a 31.1% ROI and a BULLISH sentiment, rising further to 2028 at $2.77 (35.6% ROI) and 2029 at $2.72 (33.4% ROI). The path continues to 2030 with a $3.03 average and 48.4% ROI, and remains generally bullish through 2032.
From 2033 onward, the forecast accelerates: 2033 average $3.49 (70.9% ROI), 2034 $3.89 (90.7% ROI), and 2035 $4.15 (103.5% ROI), with sentiment remaining BULLISH. The horizon extends to 2040 with an average of $5.32 (160.7% ROI) and to 2050 with an average of $8.03 (293.7% ROI), all labeled BULLISH.
These figures illustrate a steady upward trajectory for the asset’s average price over time, alongside rising potential returns, while recognizing that forecast uncertainty and market dynamics can alter outcomes.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.03 with a min of $2.15 and a max of $4.61, a ROI of 48.4%, and a BULLISH sentiment.
Yes. The 2027 forecast lists an average price of $2.67 with a min of $2.08 and a max of $3.66, a ROI of 31.1%, and a BULLISH sentiment.
Current price is $2.04 and market cap is $3.53M.
The 30-day range is $1.63 to $2.55.
By 2050 the average price is $8.03 with a min of $4.00 and a max of $16.13, a ROI of 293.7%, and a BULLISH sentiment.
XORTX Therapeutics Inc. Community Discussion
0Share your XORTX Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.